Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of KDH-136 intracanal administration after pulpal necrosis or pulpectomy
jRCT2031230695Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of KDH-136 in pulpal necrosis and pulpectomy (2 arms), sponsored by Kowa Company, Ltd. Primary endpoints: Safety and Efficacy. Started Mar 2024; status: completed.
02
Drugs
KDH-136
03
Conditions
pulpal necrosispulpectomy
Beyond the preview
Go deeper on jRCT2031230695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230695.